Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stent thrombosis revisited

A H Gershlick1, R K Aggarwal

  • 1Academic Division of Cardiology, Glenfield Hospital, Leicester, U.K.

European Heart Journal
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Less aggressive antithrombotic regimens, like aspirin alone or with ticlopidine, show promise after stent implantation, improving outcomes. Higher-risk patients may benefit from combined therapies, while full anticoagulation remains for specific cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Navigating the heights of environmental impacts of the Himalayan waste management system through life cycle assessment approach.

Environmental monitoring and assessment·2025
Same author

Greenhouse gas emission potential of sewage treatment plants in Himachal Pradesh.

Scientific reports·2023
Same author

Clinical outcomes of patients discharged from the Rapid Access Chest Pain Clinic with non-anginal chest pain: A retrospective cohort study.

International journal of cardiology·2019
Same author

Von Willebrand factor, endothelial damage and ocular disease.

Ocular immunology and inflammation·2012
Same author

Emergence of pandemic 2009 influenza A H1N1, India.

The Indian journal of medical research·2012
Same author

Psoriasis-associated genetic polymorphism in North Indian population in the CCHCR1 gene and in a genomic segment flanking the HLA-C region.

Disease markers·2011
Same journal

The surgical collateralization theory: has the beautiful hypothesis been killed by the ugly facts?

European heart journal·2026
Same journal

Beyond single measurement: additional considerations for high-sensitivity C-reactive protein in cardiovascular risk prediction.

European heart journal·2026
Same journal

Brain mineralocorticoid receptor activation and antagonism in heart failure with preserved ejection fraction: a hypothesis.

European heart journal·2026
Same journal

Myths and misconceptions about high-sensitivity C-reactive protein as a marker of residual inflammatory risk.

European heart journal·2026
Same journal

Vascular Ehlers-Danlos syndrome: should we treat asymptomatic patients?

European heart journal·2026
Same journal

Impactful trials on dyslipidaemias, fractional flow reserve, beta-blockers, and peripheral artery disease.

European heart journal·2026
See all related articles

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Thrombosis Research

Background:

  • The selection of antithrombotic therapy following stent implantation has become more complex.
  • Improved complication rates and reduced hospital stays are associated with less aggressive antithrombotic regimens.

Purpose of the Study:

  • To evaluate the efficacy and safety of various antithrombotic regimens after stent implantation.
  • To provide guidance on selecting appropriate antithrombotic strategies based on patient risk and stenting scenarios.

Main Methods:

  • Review of current antithrombotic strategies and their outcomes.
  • Analysis of clinical scenarios including de novo stenting in large vessels and high-risk patient profiles.
  • Consideration of intravascular ultrasound criteria for regimen selection.

Related Experiment Videos

Main Results:

  • Less aggressive regimens, such as aspirin alone or with ticlopidine, are effective for de novo stenting in large vessels with good results.
  • For high-risk patients, ticlopidine and aspirin, alone or with low molecular weight heparin, are viable options.
  • Full anticoagulation is still indicated for established or threatened vessel closure.
  • Early stent deployment is recommended to minimize the need for bailout stenting.

Conclusions:

  • Antithrombotic choices should be tailored to patient risk and specific stenting situations.
  • Further advancements are needed for non-thrombogenic stents suitable for all vessel sizes.